In glioblastomas, nuclear Survivin was shown to predict poor survival after radiotherapy [50] and combined radio-chemotherapy [51]—predictive value for TMZ therapy alone, in MGMT-negative tumors, has not been accessed yet. This evidence concerns the gene MGMT and glioblastoma.